# Consensus checked against original sources: Replacing Saturated Fat with Linoleic-Acid-Rich Oils

Cutoff: 13 October 2026. Consensus supports discovery and checks of specific source aspects; it is not a primary study, a full-paper audit or a causal probability meter.

## Consensus calls the cholesterol-death association within-arm and describes9423participants without adequately separating the recovered analyses.
Actual original Methods/Results show that the detailed longitudinal cohort comprised2355people exposed for at least one year, full randomized raw data were not recovered, and the adjusted cholesterol-death association pooled both arms with no detected cholesterol-by-arm interaction. This is observational mediator covariance, not randomized proof that cholesterol lowering causes death. The broader9423cohort's mortality graphs and the149partially recovered autopsies are separate evidence components. [Original PMID27071971](https://pubmed.ncbi.nlm.nih.gov/27071971/). Access: full_text_partial.

## Consensus says Sydney significantly increased all-cause mortality along with coronary mortality.
Actual selected original Results give all-causeP=.051, a borderline result rounded in the abstract; coronary and cardiovascular mortality contrasts were significant. The458men, median39-month horizon and highLA safflower-oil/margarine intervention are verified, while usual-modern-oil toxicity and an inflammatory mediator are not demonstrated. [Original PMID23386268](https://pubmed.ncbi.nlm.nih.gov/23386268/). Access: full_text_partial.

## Consensus describes Minnesota as lipid lowering without clinical benefit.
The original1989trial abstract agrees for overall cardiovascular events and mortality. It also reports a mean dietary exposure of384days despite the longer trial, and the institutional food replacement changed several lipid-related features. The1989and2016reports belong to one parent trial; the recovered report's meta-analysis does not count as an additional original clinical experiment. [Original PMID2643423](https://pubmed.ncbi.nlm.nih.gov/2643423/). Access: abstract_metadata.

## Consensus groups classic historical diets as randomized clinical oil trials and mentions their design limitations.
The actual Finnish abstract describes one hospital on the diet, the other as control, then reversal after six years. Despite anRCTmetadata tag, this is treated as a controlled hospital-period natural experiment, with the male favourable result retained and the women's nonsignificant report grouped under the same parent programme. [Original PMID393644](https://pubmed.ncbi.nlm.nih.gov/393644/). Access: abstract_metadata.

## Consensus says vegetable-oil substitution reliably lowers LDLand warns that biomarkers do not guarantee survival benefit.
The originalDIVAStrial confirms16-week isoenergetic replacement and lower LDLbut a null primary flow-mediated-dilatation endpoint. Its17-20%mortality reduction was estimated from lipid change, not observed. This source supports experimental lipid response, not a coronary-event crossing. [Original PMID26016869](https://pubmed.ncbi.nlm.nih.gov/26016869/). Access: abstract_metadata.

## Consensus says human feeding studies largely contradict a blanket LA-induced systemic-inflammation claim.
The original67-person randomized isocaloric trial found lower liver fat and selected inflammatory signals with vegetableomega6versus butter and no reported oxidative-stress or proinflammatory signal. Some lipid findings were restricted to postrandomization compliant participants. Short markers cannot prove universal safety or long-term event protection, but the unfavourable-inflammation prediction did not hold in this experiment. [Original PMID22492369](https://pubmed.ncbi.nlm.nih.gov/22492369/). Access: abstract_metadata.

## Consensus correctly identifies a self-selected2029-person carnivore survey with perceived benefits and elevated median LDLin a subset.
Actual original Methods confirm recruitment through existing carnivore social-media communities and at least six months of diet maintenance, with self-reported measurements and no balanced-diet control. Selected Results retain perceived benefits, improved glycemic reports and high LDLwithout converting these into adjudicated long-term cardiovascular superiority. [Original PMID34934897](https://pubmed.ncbi.nlm.nih.gov/34934897/). Access: full_text_partial.

## Consensus discusses mixedomega3/omega6diets separately from pureLAand notes composition confounding.
The originalLyonallocated programme lowered coronary events while LAintake decreased and ALA/oleic exposure increased, with similar serum lipids. It is a positive whole-pattern result and does not prove LAharm. More generally, our registered claim is LA-rich oils, not pureLA, so anALA-containing oil is not excluded merely for containingALA. [Original PMID7911176](https://pubmed.ncbi.nlm.nih.gov/7911176/). Access: abstract_metadata.

## Consensus's brief clinical summary does not resolve the differing circulating-fatty-acid MRresults.
The examined originalMRreports favourable linoleic-CAD estimates using allele scores and pleiotropy-robust summary methods. It is retained as causal-inference support, while the exposure is lifelong circulating metabolism rather than assigned isocaloric oil replacement. It does not independently verify the clinical dietary bridge. [Original PMID33924952](https://pubmed.ncbi.nlm.nih.gov/33924952/). Access: abstract_metadata.

## Consensus emphasizes heterogeneous trial and biomarker evidence but does not identify this conflicting largeMRanalysis in its brief response.
The originallargePUFAGWAS/MRreport found inconsistent linoleic estimates across methods and endpoints and important LDL/FADSlocus sensitivity. Those assumptions and shared metabolic pathways are examined rather than treating everyMRpaper as either simple association or independently convergent proof. [Original PMID35692035](https://pubmed.ncbi.nlm.nih.gov/35692035/). Access: abstract_metadata.

## Consensus says controlled interventions do not elevate systemic inflammatory biomarkers in general.
FADSDIETprovides a relevant qualification: short CRPand fatty-acid responses differed byFADS1genotype among62men receiving enrichment. There was no randomized saturated-fat comparator and no clinical coronary inflammatory endpoint. The result narrows a universal no-marker-response claim without establishing usual-intake clinical harm. [Original PMID30624587](https://pubmed.ncbi.nlm.nih.gov/30624587/). Access: abstract_metadata.

## Consensus's brief overview calls the evidence conflicting but highlights recovered clinical trials more than prospective adipose-exposure nulls.
The originalDanishcase-cohort study found no adiposeLAassociation with infarction after16years or shorter horizons. That null is retained alongside favourableCHSandEPICNorfolkassociations, preventing selective citation of only positive or adverse cohorts. [Original PMID33687534](https://pubmed.ncbi.nlm.nih.gov/33687534/). Access: abstract_metadata.

## Consensus identifies replacement-comparator and dietary-context gaps.
The originalDutch20,069-person study found no coronary incidence association across LAintake differences mainly replacing carbohydrate. It is not a randomized saturated-fat replacement trial, so its null cannot directly refute the registered oil-swap proposition. [Original PMID21816117](https://pubmed.ncbi.nlm.nih.gov/21816117/). Access: abstract_metadata.

## Methods
Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.